Article

Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variants

2022-01-28

Abstract excerpt

The SARS-CoV-2 vaccine BBV152/Covaxin is well-tolerated and was shown to be 77.8% efficacious against symptomatic and 93.4% efficacious against severe symptomatic COVID-19 disease in adults. Previous studies have shown that sera from Covaxin vaccinated individuals have neutralizing activity against B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), B.1.1.28 (Zeta), and B.1.617.1 (Kappa) SARS-CoV-2 variants. The B...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6c9c62f0-144d-576d-b71d-124ca2e79012
DOI: 10.1101/2022.01.24.22269189

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variantsDOI 10.1101/2022.01.24.22269189Read

SARS-CoV-2 vaccine-breakthrough infections (VBIs) by Omicron (B.1.1.529) variant and consequences in structural and functional impactSemantic proximity Read

Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variantSemantic proximity Read

Effectiveness of XBB.1.5 Vaccines Against Omicron SubvariantsSemantic proximity Read

Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants, including Omicron sublineagesSemantic proximity Read

Vaccines Elicit Highly Cross-Reactive Cellular Immunity to the SARS-CoV-2 Omicron VariantSemantic proximity Read

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particlesSemantic proximity Read

The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivitySemantic proximity Read

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responsesSemantic proximity Read

BBIBP-CorV Vaccination Reduces COVID-19 Severity Rate and Accelerates Anti-Viral Antibody Responses in Heterologous Omicron InfectionSemantic proximity Read

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 VaccineSemantic proximity Read

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variantSemantic proximity Read

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concernSemantic proximity Read